GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of help me understand FLOW, I have read the wiki twice — 19 comments in the full submission. View in context.
191
c/trialwatch·submitted 2 months ago by u/zaid_roos

help me understand FLOW, I have read the wiki twice

Press Releasebranch of 9 comments

FLOW. That is the whole post, but I will justify it. Everything else people worry about in c/coa is downstream of it. Titration speed, reflux, the endless dose arguments — most of it resolves if you sort FLOW out first, and almost nobody does. I say this having got it wrong for 22 months. My fasting insulin was the…

Read the full submission and all 19 comments →

This branch

9 comments, started 2 months ago
u/iman_castellanos14 points·2 months ago

the relative risk reduction in headlines is not the whole story

replysharereportpermalink
u/sofia_ferreira9 points·2 months ago·edited

the 18 week readout is different from the 6 week readout

replysharereportpermalink
u/week_four_wall10 points·2 months ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/sofia_wikstrom6 points·2 months ago

the 18 week readout is different from the 6 week readout

Disagree on that part. 97.9% and 97.6% on the same vial is normal.

replysharereportpermalink
u/zaid_roosOP4 points·2 months ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink
u/zaid_roosOP3 points·2 months ago

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink
u/piotr_bruun10 points·2 months ago

the relative risk reduction in headlines is not the whole story

replysharereportpermalink
u/customs_seizure_sid3 points·2 months ago·edited

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink
u/foam_head_fred8 points·2 months ago

the discontinuation arms are the interesting part, not the STEP endpoints

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →